Two Clinical Trials Show Increased Progression-Free Survival With Addition of Immunotherapy in Endometrial Cancer


Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

Results from 2 clinical trials, presented at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer, demonstrated that adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer.

Credit: Vitalii Vodolazskyi -

Credit: Vitalii Vodolazskyi -

The first trial presented, NRG-GY018, involved 816 patients with stage 3/4A, 4B, or recurrent endometrial cancer. Participants were randomized 1-to-1 to receive either immunotherapy pembrolizumab plus chemotherapy or placebo plus chemotherapy across 6 cycles, followed by up to 14 cycles of maintenance pembrolizumab or placebo. Importantly, patients in the mismatch repair-proficient endometrial cancer cohort who received immunotherapy and chemotherapy experienced PFS for 11.7 months versus 8.7 months among those receiving chemotherapy alone, with managed adverse effects (AEs).

The second trial, ENGOT-EN6-NSGO/GOG-3031/RUBY, included 494 eligible patients with first recurrent or primary advanced stage 3 or 4 endometrial cancer. Participants were randomized 1-to-1 to receive either immunotherapy dostarlimab plus chemotherapy followed by monotherapy or placebo plus chemotherapy, then monotherapy.

Among the 245 patients who received both immunotherapy and chemotherapy in the RUBY trial, there were statistically significant and clinically meaningful PFS benefits across all populations compared with 249 patients treated with chemotherapy alone. Additionally, investigators observed an early trend toward improved overall survival in all populations.

“Patients with advanced stage or recurrent endometrial cancer, the most common type of gynecologic cancer in the United States, face a poor prognosis with limited treatment options,” said NRG-GY018 trial investigator Ramez N. Eskander, MD, in a press release. “This is particularly notable in patients who progress after platinum-based adjuvant therapy with disease not amenable to curative surgery or radiation. In the GY-018 study, we saw clinically meaningful improvement in PFS in both study populations—an encouraging new finding. Future analysis will examine overall survival and quality of life outcomes.”


Two Clinical Trials Reveal Addition of Immunotherapy to Chemotherapy Regimen Increases Progression-Free Survival in Endometrial Cancer Patients. News release. Society of Gynecologic Oncology. March 27, 2023. Accessed April 6, 2023.

Related Videos
Woman with pink ribbon on color background. Breast cancer awareness concept | Image Credit: Pixel-Shot -
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store- Image credit: C Daniels/ |
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto -
A female doctor sits at her desk and talks to a female patient while looking at her mammogram | Image Credit: lordn -
Doctor holding a digital tablet with x-ray of brain and skull skeleton. Headache, meningitis and migraine concept - Image credit: Steph photographies |
Woman Physician Talking With Her Patient | Image Credit: LStockStudio -
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint |
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan |
© 2023 MJH Life Sciences

All rights reserved.